Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: VaxigripTetra™ by Sanofi, Inc.
Biological: Flublok™ Quadrivalent by Sanofi, Inc.

Registration Number: NCT04523324

Lead Sponsor: Centers for Disease Control and Prevention

Brief Summary: This randomized, open-label, active-controlled trial will assess humoral immune responses to a single dose of 2019-20 recombinant hemagglutinin quadrivalent influenza vaccines (RIV4) compared with standard egg-based unadjuvanted quadrivalent influenza vaccines (IIV4) among healthcare personnel (HCP) vaccinated during the previous 2018-19 season with IIV4. The trial will be conducted at two hospital sites in Israel during the 2019-20 influenza season among HCP who were enrolled in the Study of Healthcare Personnel with Influenza and other Respiratory Viruses in Israel (SHIRI).

Detailed Description: This is a randomized, open-label study design. Starting in July 2019, approximately 550 to 700 HCP from two hospitals (275-350 per hospital site) in Israel will be enrolled. Following completion of a written consent form, participants will complete an enrollment survey and grant permission for review of information collected during the SHIRI study, including vaccination status and immune response during the SHIRI study years. Participants will complete an enrollment survey and grant permission to include and integrate information collected during the SHIRI study into the current study's data, including health history, influenza vaccination history, and immune response to vaccination during the SHIRI study years. HCP will be randomly assigned 1:1 to receive a single dose of IIV4 licensed in Israel (expected to be Vaxigrip® Quadrivalent, 15µg of HA per strain) or RIV4 (Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain) during August-October of 2019. Adverse events following vaccination will be monitored and documented. Blood specimens will be collected prior to vaccination and approximately 28 days after to evaluate immune responses to vaccination.

Eligible HCP who were already vaccinated with Vaxigrip, the vaccine that is routinely available in Israel, at the time they are approached to join the study, will be invited to join the study as part of the Vaxigrip arm. Like randomized participants, participants who were vaccinated with Vaxigrip outside the study will complete a written consent form, an enrollment survey and grant permission for review of information collected during the SHIRI study, including vaccination status and immune response during the SHIRI study years. As part of the consent form, participants will record the estimated date that they received the vaccine, and the location, and will authorize study staff to verify the date of current-year Vaxigrip vaccination in the Clalit EMR and with the hospital vaccination staff. Participants will complete an enrollment survey and grant permission to include and integrate information collected during the SHIRI study into the current study's data, including health history, influenza vaccination history, and immune response to vaccination during the SHIRI study years. Blood specimens will be collected approximately 28 days after to evaluate immune responses to vaccination.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 577

Inclusion Criteria

Aged ≥18
Current member of Clalit Health Services
Consent to randomized receipt of influenza vaccination with either RIV4 or IIV4, or, if already vaccinated in the current year outside of the study, consent to receive a post-vaccination blood draw
Participated in the SHIRI study and received influenza vaccination during the 2018-19 influenza season (Group 1)
Participated in any year of the SHIRI study, not vaccinated in 2018-2019, but vaccinated in at least one study year (Group 1 supplemental)
Participated in the SHIRI study during all three years, regardless of vaccination status (Group 1 supplemental)
Participated in any year of the SHIRI study and had PCR-confirmed influenza virus infection during any of the three study years (Group 2)

Exclusion Criteria

Already received an influenza vaccine during the current influenza season
Not willing or able to get the flu vaccines being used in this study;
Previous hypersensitivity reaction to the study vaccines, or any vaccine, as reported by the subject
Received any non-influenza vaccine (e.g., Hepatitis B or other vaccine recommended for HCP) in the 4 weeks prior to the first study visit or plans to receive a vaccine in the 4 weeks following the first study visit
Currently participating in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication), or has received an experimental agent within 1 month prior to enrollment in this study, or expects to receive an experimental agent during participation in this study.
Any condition or employment status that the potential participant or local study site principle investigator (PI) believes may interfere with successful completion of the study prior to December 2019, including being currently pregnant.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
IIV4 (Vaxigrip Quadrivalent)	VaxigripTetra™ by Sanofi, Inc.	VaxigripTetra™ by Sanofi, Inc., 15µg of HA per strain, egg-based
RIV4 (Flublok Quadrivalent)	Flublok™ Quadrivalent by Sanofi, Inc.	Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain

Primary Outcome Measures

Name	Time	Method
Geometric Mean Titer Ratio (GMR) Against Egg-grown Influenza Virus A/H3N2	0 to 28 days after vaccination	The ratio of the pre- vs. post-vaccination titer against egg-grown influenza virus A/H3N2 following a single dose of RIV4 versus IIV4.
Post-vaccination Geometric Mean Titer Against Influenza B(Victoria)	Day 28 days after vaccination	The geometric mean of antibody titers following a single dose of RIV4 or IIV4 as measured by hemagglutination inhibition (HI) for Influenza B(Victoria)
Post-vaccination GMT Against Cell-grown Influenza Virus A/H3N2	Day 28 days after vaccination	The geometric mean of antibody titers following a single dose of RIV4 or IIV4 as measured by hemagglutination inhibition (HI) for cell-grown influenza virus A/H3N2
Geometric Mean Titer Ratio (GMR) Against Influenza B(Yamagata)	0 to 28 days after vaccination	The ratio of the pre- vs. post-vaccination titer against Influenza B(Yamagata) following a single dose of RIV4 versus IIV4.
Post-vaccination Geometric Mean Titer Against Influenza Virus A/H1N1	Day 28 days after vaccination	The geometric mean of antibody titers following a single dose of RIV4 or IIV4 as measured by hemagglutination inhibition (HI) for influenza virus A/H1N1
Geometric Mean Titer Ratio (GMR) Against Influenza Virus A/H1N1	0 to 28 days after vaccination	The ratio of the pre- vs. post-vaccination titer against influenza virus A/H1N1 following a single dose of RIV4 versus IIV4.
Geometric Mean Titer Ratio (GMR) Against Influenza B(Victoria)	0 to 28 days after vaccination	The ratio of the pre- vs. post-vaccination titer against Influenza B(Victoria) following a single dose of RIV4 versus IIV4.
Post-vaccination Geometric Mean Titer Against Influenza B(Yamagata)	Day 28 days after vaccination	The geometric mean of antibody titers following a single dose of RIV4 or IIV4 as measured by hemagglutination inhibition (HI) for Influenza B(Yamagata)
Post-vaccination Geometric Mean Titer Against Egg-grown Influenza Virus A/H3N2	Day 28 days after vaccination	The geometric mean of antibody titers following a single dose of RIV4 or IIV4 as measured by hemagglutination inhibition (HI) for egg-grown influenza virus A/H3N2
Geometric Mean Titer Ratio (GMR) Against Cell-grown Influenza Virus A/H3N2	0 to 28 days after vaccination	The ratio of the pre- vs. post-vaccination titer against cell-grown influenza virus A/H3N2 following a single dose of RIV4 versus IIV4.